S991
Clinical - Oligometastatic cancer
ESTRO 2026
p=0.002) were significantly associated to longer LPFS.Similarly, BED100 (HR 0.99, p=0.001), number of treated lesion (HR 0.70, p=0.002), site of irradiated lesions (HR 1.07, p= 0.01) and oligometastatic state (HR 1.22, p= 0.01) correlated with improved OS. Conclusion: SBRT is a safe and effective treatment option for elderly patients with oligometastatic disease, achieving high rates of durable local control and survival without being influenced by performance status or comorbidity burden. These findings support the use of SBRT as a valuable therapeutic alternative even in very elderly and comorbid patients, potentially expanding access to curative-intent local treatments in this growing population. Keywords: elderly, oligometastases, SBRT Digital Poster 4792 Long term Outcomes following stereotactic ablative radiotherapy (SABR) for Melanoma Liver Metastases Meenakshi Jeeva 1 , Aruz Mesci 1 , John Kim 1 , Ali Hosni Abdalaty 1 , Marcus Butler 2 , Laura Dawson 1 , Philip Wong 1 1 Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada. 2 Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada Purpose/Objective: Immunotherapy (IO) and targeted therapies improve survival in metastatic melanoma, though benefits are limited in non-cutaneous subtypes. This study reports outcomes of SABR for melanoma liver metastases refractory to or unsuitable for systemic therapy. Material/Methods: This ethics-approved review included patients with liver metastases treated with SABR (2007–2025) who had controlled primaries and an oligometastatic/oligoprogressive state ( ≤ 3 sites, ≤ 5 metastases). The primary endpoint was local control (LC); secondary endpoints included progression-free survival (PFS) and overall survival (OS). Results:
Between July 2013 to February 2025, 299 patients for a total of 468 lesions were treated. Patients characteristic are summarized in Table 1. Mean follow- up was 24.66 ± 18.71 months. The 1- and 2-year LPFS rates were 90.7% and 80.8%; median not reached. The 1- and 2-year STFS rates were 77.1% and 69.7.%; median not reached.The 1- and 2-years PFS rates were 48.7% and 30%; median PFS was 11.76 months. The 1- and 2-year OS rates were 84.0 % and 64.2 %; median OS was 33.24 months (28.7-38.1).At univariate analysis, BED100 (HR 0.99, p=0.036), number of treated lesion (HR 0.57, p=0.04), primary tumour site (HR 0.76, p=0.005) and oligometastatic time (HR 0.43,
Twenty-nine patients (median age 62, IQR 58–75) with 67 liver metastases were reviewed. Primary sites were uveal (22, 75.8%), cutaneous (4, 13.8%), mucosal (2, 6.9%), and unknown (1, 3.4%). The median time from original diagnosis to developing liver metastases was 28 months (IQR 19.5–46.5). At the time of liver SABR, 7
Made with FlippingBook - Share PDF online